Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer.

Kumbhar, P; Kole, K; Khadake, V; Marale, P; Manjappa, A; Nadaf, S; Jadhav, R; Patil, A; Singh, SK; Dua, K; Jha, NK; Disouza, J; Patravale, V

Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer.

Kumbhar, P Kole, K Khadake, V Marale, P Manjappa, A Nadaf, S Jadhav, R Patil, A Singh, SK Dua, K

Jha, NK Disouza, J Patravale, V

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: J Control Release, 2022, 349, pp. 812-830
Issue Date:: 2022-08-03

Closed Access

	Filename	Description	Size
	Breast Cancer_Nanoparticulate_1-s2.0-S0168365922004746-main.pdf	Published version	10.89 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kumbhar, P
dc.contributor.author	Kole, K
dc.contributor.author	Khadake, V
dc.contributor.author	Marale, P
dc.contributor.author	Manjappa, A
dc.contributor.author	Nadaf, S
dc.contributor.author	Jadhav, R
dc.contributor.author	Patil, A
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Jha, NK
dc.contributor.author	Disouza, J
dc.contributor.author	Patravale, V
dc.date.accessioned	2022-08-18T11:52:58Z
dc.date.available	2022-07-26
dc.date.available	2022-08-18T11:52:58Z
dc.date.issued	2022-08-03
dc.identifier.citation	J Control Release, 2022, 349, pp. 812-830
dc.identifier.issn	0168-3659
dc.identifier.issn	1873-4995
dc.identifier.uri	http://hdl.handle.net/10453/160462
dc.description.abstract	Breast cancer (BC) is a highly diagnosed and topmost cause of death in females worldwide. Drug repurposing (DR) has shown great potential against BC by overcoming major shortcomings of approved anticancer therapeutics. However, poor physicochemical properties, pharmacokinetic performance, stability, non-selectivity to tumors, and side effects are severe hurdles in repurposed drug delivery against BC. The variety of nanocarriers (NCs) has shown great promise in delivering repurposed therapeutics for effective treatment of BC via improving solubility, stability, tumor selectivity and reducing toxicity. Besides, delivering repurposed cargos via theranostic NCs can be helpful in the quick diagnosis and treatment of BC. Localized delivery of repurposed candidates through apt NCs can diminish the systemic side effects and improve anti-tumor effectiveness. However, breast tumor variability and tumor microenvironment have created several challenges to nanoparticulate delivery of repurposed cargos. This review focuses on DR as an ingenious strategy to treat BC and circumvent the drawbacks of approved anticancer therapeutics. Various nanoparticulate avenues delivering repurposed therapeutics, including non-oncology cargos and vaccines to target BC effectively, are discussed along with case studies. Moreover, clinical trial information on repurposed medications and vaccines for the treatment of BC is covered along with various obstacles in nanoparticulate drug delivery against cancer that have been so far identified. In a nutshell, DR and drug delivery of repurposed drugs via NCs appears to be a propitious approach in devastating BC.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	J Control Release
dc.relation.isbasedon	10.1016/j.jconrel.2022.07.039
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0903 Biomedical Engineering, 0904 Chemical Engineering, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.title	Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer.
dc.type	Journal Article
utslib.citation.volume	349
utslib.location.activity	Netherlands
utslib.for	0903 Biomedical Engineering
utslib.for	0904 Chemical Engineering
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-08-18T11:52:51Z
pubs.publication-status	Published online
pubs.volume	349

Abstract:

Breast cancer (BC) is a highly diagnosed and topmost cause of death in females worldwide. Drug repurposing (DR) has shown great potential against BC by overcoming major shortcomings of approved anticancer therapeutics. However, poor physicochemical properties, pharmacokinetic performance, stability, non-selectivity to tumors, and side effects are severe hurdles in repurposed drug delivery against BC. The variety of nanocarriers (NCs) has shown great promise in delivering repurposed therapeutics for effective treatment of BC via improving solubility, stability, tumor selectivity and reducing toxicity. Besides, delivering repurposed cargos via theranostic NCs can be helpful in the quick diagnosis and treatment of BC. Localized delivery of repurposed candidates through apt NCs can diminish the systemic side effects and improve anti-tumor effectiveness. However, breast tumor variability and tumor microenvironment have created several challenges to nanoparticulate delivery of repurposed cargos. This review focuses on DR as an ingenious strategy to treat BC and circumvent the drawbacks of approved anticancer therapeutics. Various nanoparticulate avenues delivering repurposed therapeutics, including non-oncology cargos and vaccines to target BC effectively, are discussed along with case studies. Moreover, clinical trial information on repurposed medications and vaccines for the treatment of BC is covered along with various obstacles in nanoparticulate drug delivery against cancer that have been so far identified. In a nutshell, DR and drug delivery of repurposed drugs via NCs appears to be a propitious approach in devastating BC.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160462